These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24829597)

  • 21. Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.
    Morsch M; Reddel SW; Ghazanfari N; Toyka KV; Phillips WD
    J Physiol; 2013 May; 591(10):2747-62. PubMed ID: 23440963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis.
    Punga AR; Sawada M; Stålberg EV
    Muscle Nerve; 2008 Mar; 37(3):300-7. PubMed ID: 18069667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Childhood-onset anti-MuSK antibody positive myasthenia gravis demonstrates a distinct clinical course.
    Takahashi Y; Sugiyama M; Ueda Y; Itoh T; Yagyu K; Shiraishi H; Ukeba-Terashita Y; Nakanishi M; Nagashima T; Imai T; Motomura M; Saitoh S
    Brain Dev; 2012 Oct; 34(9):784-6. PubMed ID: 22277190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Myasthenia gravis with anti-acetylcholine receptor antibody or anti-muscle specific kinase antibody].
    Konishi T
    Brain Nerve; 2011 Jul; 63(7):695-704. PubMed ID: 21747139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Correlation between clinical manifestation, prognosis and antibody in anti-muscle-specific tyrosine kinase antibody positive myasthenia gravis].
    Tan Y; Zhu L; Huang YY; Shi JY; Li J; Li K; Guan YZ; Cui LY
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(31):2433-2437. PubMed ID: 34399555
    [No Abstract]   [Full Text] [Related]  

  • 27. Acetylcholinesterase inhibitors in MG: to be or not to be?
    Punga AR; Stålberg E
    Muscle Nerve; 2009 Jun; 39(6):724-8. PubMed ID: 19260048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.
    Küçükerden M; Huda R; Tüzün E; Yılmaz A; Skriapa L; Trakas N; Strait RT; Finkelman FD; Kabadayı S; Zisimopoulou P; Tzartos S; Christadoss P
    J Neuroimmunol; 2016 Jun; 295-296():84-92. PubMed ID: 27235354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mouse passive-transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure.
    Ghazanfari N; Trajanovska S; Morsch M; Liang SX; Reddel SW; Phillips WD
    Ann N Y Acad Sci; 2018 Jan; 1412(1):54-61. PubMed ID: 29125188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.
    Oh SJ
    J Clin Neurol; 2009 Jun; 5(2):53-64. PubMed ID: 19587811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
    Vincent A; Leite MI
    Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Muscle-specific receptor tyrosine kinase antibody-positive and seronegative myasthenia gravis.
    Muppidi S; Wolfe GI
    Front Neurol Neurosci; 2009; 26():109-119. PubMed ID: 19349708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients.
    Li Y; Guptill JT; Russo MA; Massey JM; Juel VC; Hobson-Webb LD; Howard JF; Chopra M; Liu W; Yi JS
    Exp Neurol; 2019 Feb; 312():43-50. PubMed ID: 30472069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anti-MuSK antibody positive myasthenia gravis with HIV infection successfully treated with cyclosporin: a case report].
    Kurokawa T; Nishiyama T; Yamamoto R; Kishida H; Hakii Y; Kuroiwa Y
    Rinsho Shinkeigaku; 2008 Sep; 48(9):666-9. PubMed ID: 19048951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status.
    Usmani A; Kwan L; Wahib-Khalil D; Trivedi J; Nations S; Sarode R
    J Clin Apher; 2019 Aug; 34(4):416-422. PubMed ID: 30779438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients.
    Yamada C; Teener JW; Davenport RD; Cooling L
    J Clin Apher; 2015 Oct; 30(5):314-9. PubMed ID: 25557356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comorbid Human Immunodeficiency Virus (HIV) and Muscle-Specific Kinase (MuSK) Myasthenia Gravis: A Case Report and Literature Review.
    Sherpa M; Metai RK; Kumar V; Hirachan T; Ahmed KU; Atkinson SJ
    Am J Case Rep; 2017 Apr; 18():427-430. PubMed ID: 28424453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrophysiological profile of the patients with MuSK positive myasthenia gravis.
    Nikolic A; Basta I; Stojanovic VR; Stevic Z; Lavrnic D
    Neurol Res; 2014 Nov; 36(11):945-9. PubMed ID: 24825477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.
    Hurst RL; Gooch CL
    Curr Neurol Neurosci Rep; 2016 Jul; 16(7):61. PubMed ID: 27170368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.